C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Total Liabilities of $94.6 million for Q1 2026, down 23.93% year-over-year from $124.4 million in Q1 2025, and down 7.68% quarter-over-quarter from $102.5 million in Q4 2025.
C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026) Analysis & Trends
C4 Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $94.6 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 23.93% year-over-year to $94.6 million; the TTM figure through Mar 2026 stood at $94.6 million (down 23.93% YoY), while the FY2025 annual figure was $102.5 million, down 23.3% from the prior year.
- Total Liabilities for Q1 2026 stood at $94.6 million, down from $102.5 million in the prior quarter.
- The five-year high for Total Liabilities was $151.0 million in Q1 2022, with the low at $94.6 million in Q1 2026.
- The 5-year median for Total Liabilities is $133.6 million (2023), against an average of $129.5 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities soared 36.86% in 2022, then decreased 23.93% in 2026.
- C4 Therapeutics' Total Liabilities stood at $141.6 million in 2022, then fell by 7.96% to $130.3 million in 2023, then gained by 2.52% to $133.6 million in 2024, then fell by 23.3% to $102.5 million in 2025, then slipped by 7.68% to $94.6 million in 2026.
- Business Quant data shows CCCC's Total Liabilities at $94.6 million in Q1 2026, $102.5 million in Q4 2025, and $111.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 112.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.14 Mn |
| Mar 31, 2026 | 94.61 Mn |
| Dec 31, 2025 | 102.49 Mn |
| Sep 30, 2025 | 111.08 Mn |
| Jun 30, 2025 | 122.46 Mn |
| Mar 31, 2025 | 124.38 Mn |
| Dec 31, 2024 | 133.62 Mn |
| Sep 30, 2024 | 133.40 Mn |
| Jun 30, 2024 | 134.04 Mn |
| Mar 31, 2024 | 140.09 Mn |
| Dec 31, 2023 | 130.34 Mn |
| Sep 30, 2023 | 116.99 Mn |
| Jun 30, 2023 | 141.30 Mn |
| Mar 31, 2023 | 133.57 Mn |
| Dec 31, 2022 | 141.61 Mn |
| Sep 30, 2022 | 143.26 Mn |
| Jun 30, 2022 | 147.88 Mn |
| Mar 31, 2022 | 150.96 Mn |
| Dec 31, 2021 | 117.16 Mn |
| Sep 30, 2021 | 109.13 Mn |